Experimental CCR5 antagonism with maraviroc in atherosclerosis-prone mice and preliminary data in humans suggest an anti-atherosclerotic effect of the drug. We assessed the impact of maraviroc treatment in persons living with HIV on subclinical indicators of atherosclerosis.

Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study

Francisci, Daniela
Conceptualization
;
Pirro, Matteo
Conceptualization
;
Schiaroli, Elisabetta;Mannarino, Massimo R;Cipriani, Sabrina;Bianconi, Vanessa;Alunno, Alessia;Bagaglia, Francesco;Bistoni, Onelia;Falcinelli, Emanuela;Bury, Loredana;Gerli, Roberto;Mannarino, Elmo;Baldelli, Franco
2019

Abstract

Experimental CCR5 antagonism with maraviroc in atherosclerosis-prone mice and preliminary data in humans suggest an anti-atherosclerotic effect of the drug. We assessed the impact of maraviroc treatment in persons living with HIV on subclinical indicators of atherosclerosis.
2019
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1449352
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 32
social impact